Skip to Content

Vinblastine Disease Interactions

There are 2 disease interactions with vinblastine:

Major

Vinblastine (Includes Vinblastine) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

The use of vinblastine is contraindicated in patients with known infectious diseases. Vinblastine can induce myelosuppression. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vinblastine. Close clinical monitoring of hematopoietic function is recommended. Vinblastine should not be used in patients with neutrophil counts below 1000/mm3.

References

  1. "Product Information. Velban (vinblastine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Vinblastine (Includes Vinblastine) ↔ Myelosuppression

Severe Potential Hazard, Low plausibility

Applies to: Bleeding, Bone Marrow Depression/Low Blood Counts, Fever

The use of vinblastine is contraindicated in patients with significant granulocytopenia. Vinblastine induces dose-dependent leukopenia. Thrombocytopenia and anemia have been reported infrequently during vinblastine therapy. Therapy with vinblastine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Velban (vinblastine)." Lilly, Eli and Company, Indianapolis, IN.

vinblastine drug Interactions

There are 372 drug interactions with vinblastine

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide